Genocea Biosciences IncのCurrent ratio
Genocea Biosciences IncのCurrent ratioは何ですか。
Genocea Biosciences IncのCurrent ratioは1.35です。
Current ratioの定義は何ですか。
流動比率は、同社が短期債務を履行するために十分なリソースを持っているかどうかを測定流動性比率です。
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
NASDAQのセクタHealth CareにおけるCurrent ratioの企業と比べるGenocea Biosciences Inc
Genocea Biosciences Incは何をしますか。
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Incと類似のcurrent ratio
- Haidilao InternationalのCurrent ratioは1.35です。
- TerrascendのCurrent ratioは1.35です。
- Park24 CoのCurrent ratioは1.35です。
- NCCのCurrent ratioは1.35です。
- Scorpio Bulkers IncのCurrent ratioは1.35です。
- Scorpio BulkersのCurrent ratioは1.35です。
- Genocea Biosciences IncのCurrent ratioは1.35です。
- Abcam PLCのCurrent ratioは1.35です。
- Torrent PharmaceuticalsのCurrent ratioは1.35です。
- Singapore TelecommunicationsのCurrent ratioは1.35です。
- Cooper-Standard IncのCurrent ratioは1.35です。
- PeerStreamのCurrent ratioは1.35です。
- Capital Product Partners L PのCurrent ratioは1.35です。